Showing 631-640 of 2293 results for "".
- Ofatumumab Achieves Better Outcomes than Teriflunomide for Relapsing MShttps://practicalneurology.com/news/ofatumumab-achieves-better-outcomes-than-teriflunomide-for-relapsing-ms/2470081/In 2 clinical trials, participants with newly diagnosed relapsing multiple sclerosis (MS) who received ofatumumab (Kesimpta; Novartis; Cambridge, MA) experienced better outcomes in terms of relapse rate, disability progression, and the number of lesions visualized on MRI scans compared with those
- Social Networks May Be a Modifiable Risk Factor for MS Progressionhttps://practicalneurology.com/news/social-networks-may-be-a-modifiable-risk-factor-for-ms-progression/2468812/Using social network surveys to identify patients with stronger vs weaker social networks (SNs), researchers found that persons with multiple sclerosis (MS) who had significantly worse memory, lower IQ, higher disability scores and larger declines in exercise and social activity participation (
- MS Susceptibility Genes Introduced to Europe 5000 Years Ago According to Study Published in Naturehttps://practicalneurology.com/news/ms-susceptibility-genes-introduced-to-europe-5000-years-ago-according-to-study-published-in-nature/2470382/Genes associated with susceptibility for multiple sclerosis (MS) may have been introduced to Northern Europe 5000 years ago, according to new study results published in Nature. The study was conducted to investigate potential causes for the significantly greater prevalence of MS among Wh
- In Memoriam: Ralph L. Sacco, MD, MS, FAHA, FAANhttps://practicalneurology.com/news/in-memoriam-ralph-l-sacco-md-ms-faha-faan/2470102/
- Hispanic/Latino Patients Experience MS Onset Earlier than White Participants, New Research Suggestshttps://practicalneurology.com/news/hispaniclatino-patients-experience-ms-onset-earlier-than-white-participants-new-research-suggests/2470201/According to research presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), the age at onset (AAO) of multiple sclerosis (MS) was on average 5 years earlier for Hispanic/Latino patient
- MS in Harmony Provides Access to the Benefits and Enjoyment of Music Therapy for Everyone Affected by Multiple Sclerosishttps://practicalneurology.com/news/ms-in-harmony-provides-access-to-the-benefits-and-enjoyment-of-music-therapy-for-everyone-affected-by-multiple-sclerosis/2469507/A new online platform, MSinHarmony.com has been launched and provides an engaging and interactive way to explore music therapy for people living with multiple sclerosis (MS). The site includes information about the music therapy and the growing body of ev
- More than 50% of Patients with MS Discontinue Infusion Therapy Owing in Part to Travel Burdenhttps://practicalneurology.com/news/more-than-50-of-patients-with-ms-discontinue-infusion-therapy-owing-to-travel-burden/2475045/Study results presented at the 2025 Annual Meeting of The Consortium of Multiple Sclerosis Centers (cMSc) demonstrated low medication adherence and persistence rates among Medicare beneficiaries with multiple sclerosis (MS) treated with infusion-based disease modifying therapies (DMTs). Most high
- 6-Year Data Reported for Kesimpta Treatment of Individuals with Early, Non-Highly Active MShttps://practicalneurology.com/news/6-year-data-reported-for-kesimpta-treatment-of-individuals-with-early-non-highly-active-ms/2474006/Six-year open-label extension (OLE) results from the ALITHIOS clinical trial (NCT03650114) demonstrated that treatment with Kesimpta (ofatumumab; Novartis, East Hanover, NJ) was safe and effective for individuals with early multiple sclerosis (MS) and non-highly active disease taking continuous t
- High-Dose Vitamin D Monotherapy Reduced Disease Activity in CIS and Early Relapsing-Remitting MShttps://practicalneurology.com/news/high-dose-vitamin-d-monotherapy-reduced-disease-activity-in-cis-and-early-relapsing-remitting-ms/2473817/High-dose vitamin D (cholecalciferol) monotherapy significantly reduced disease activity in patients with clinically isolated syndrome (CIS) and early relapsing-remitting multiple sclerosis (RRMS) according to results of the D-Lay MS clinical trial (NCT01817166) published in JAMA. Conduc
- Research Presented at ANA 2024 Reveals Association Between Paramagnetic Rim Lesions and Disability/Disease Progression in People with MShttps://practicalneurology.com/news/research-presented-at-ana-2024-reveals-association-between-paramagnetic-rim-lesions-and-disabilitydisease-progression-in-people-with-ms/2470577/For people with multiple sclerosis (MS), a higher number of persisting paramagnetic rim lesions (PRLs) was associated with increased odds of progression independent of relapse activity (PIRA) and confirmed disability progression (CDP), according to data presented at the 2024 annual meeting of the